Hosted on MSN1m
Merck and Eisai report mixed results in Phase 3 cancer trialAnalyst firms, including BMO Capital Markets and Bernstein, have adjusted their ratings on Merck's stock, citing various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback